BIO 2025
Energenesis Highlights Investigational Parkinson’s Disease Therapy
ENERGI-F705PD is an oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis.
Energenesis Biomedical Co. Ltd., a clinical-stage biotechnology company, will showcase its ENERGI Platform and provide a key update on its investigational Parkinson’s disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential, at the BIO International Convention 2025.
ENERGI-F705PD is an oral sustained-release therapy in development for Parkinson’s disease, designed to address the underlying pathogenesis. It aims to combat the root causes of Parkinson’s by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis.
Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment.
“We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025,” said Dr. Han-Min Chen, CEO of Energenesis Biomedical. “Parkinson’s disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy.”
